US 10,117,942 B2Granted

Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery

AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine

InventorsAnu Puri, Robert P. Blumenthal, Amit Joshi, Darayash B. Tata, Mathias Viard

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Embodiments of photoactivatable, lipid-based nanoparticles are disclosed, as well as methods of making and using the nanoparticles. Pharmaceutical compositions including the nanoparticles also are disclosed. The lipid-based nanoparticles include a vesicle wall surrounding a cavity, wherein the vesicle wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine (DPPC), and (ii) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The nanoparticles may further include an agent within the cavity.

Claims21

Dependent claims

A photoactivatable lipid-based nanoparticle, comprising:

a vesicle wall surrounding a cavity, the vesicle wall comprising
(i) a lipid bilayer comprising
(a) from 10 mol % to 20 mol % 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC),
(b) from 3 mol % to 5 mol % 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol) (DSPE-PEG), and
(c) dipalmitoylphosphatidylcholine (DPPC), and
(ii) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer,
wherein the vesicle wall has a lipid:HPPH weight ratio from 80:1 to 10:1, and wherein the lipid bilayer is destabilized by targeted application of light having a wavelength of 650-670 nm and a selected intensity for an effective period of time.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/904,385Filed 9 Jul 2014 · us provisional application
Priority: 12 Jul 2013
Published: US 2016/0136289 A119 May 2016
Granted: 6 Nov 2018
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 47/546
Heterocyclic compounds: porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/1271
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant: non-conventional liposomes,…
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…

Family

Application61/845,861Us provisional application · filed 12 Jul 2013
US 2016/0136289 A1Pre-grant publication · published 19 May 2016
US 10,117,942 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key